IR@PKUHSC  > 北京大学第二临床医学院  > 眼科
学科主题临床医学
Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy
Jiang, Yanrong; Liang, Xiaoying; Li, Xiaoxin; Tao, Yong; Wang, Kai
关键词Avastin Clinical Efficacy Intravitreal Bevacizumab Iris Neovascularization Proliferative Diabetic Retinopathy Vascular Endothelial Growth Factor Vegf Antibody
刊名ACTA OPHTHALMOLOGICA
2009-11-01
DOI10.1111/j.1755-3768.2008.01353.x
87期:7页:736-740
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Ophthalmology
研究领域[WOS]Ophthalmology
关键词[WOS]ENDOTHELIAL GROWTH-FACTOR ; VASCULAR-PERMEABILITY FACTOR ; MONOCLONAL-ANTIBODY ; RUBEOSIS IRIDIS ; CELLS SECRETE ; AVASTIN ; THERAPY
英文摘要

Purpose:

To evaluate the therapeutic effect of intravitreal bevacizumab (Avastin (R)) (IVB) in the treatment of iris neovascularization (INV) in proliferative diabetic retinopathy (PDR).

Methods:

A retrospective analysis on data collected from 28 eyes of 22 patients with PDR was performed. The analysis included grading of INV, visual acuity (VA) and intraocular pressure (IOP) prior to and after IVB treatment.

Results:

Significant regression was noted in 20 eyes (71.4%); six eyes (21.4%) showed partial regression; no change or worsening was observed in two eyes (7.2%). VA (measured with a Snellen acuity chart) improved in five eyes (17.9%) while the remaining 23 eyes (82.1%) had no improvement. In the 11 eyes with preoperative neovascular glaucoma, IOP decreased in 10 eyes (91%) and increased in one eye (9%) after treatment.

Conclusion:

IVB treatment of INV in PDR patients shows a promising short-term result. Further studies are needed to evaluate long-term results.

语种英语
WOS记录号WOS:000270999300008
项目编号7062065 ; 2005CB724307 ; RDB2007-46
资助机构Beijing Natural Science Foundation ; National Basic Research Program of China (973 Program) ; Fund of the People&prime ; s Hospital of Peking University
引用统计
被引频次:18[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54371
专题北京大学第二临床医学院_眼科
作者单位Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Yanrong,Liang, Xiaoying,Li, Xiaoxin,et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy[J]. ACTA OPHTHALMOLOGICA,2009,87(7):736-740.
APA Jiang, Yanrong,Liang, Xiaoying,Li, Xiaoxin,Tao, Yong,&Wang, Kai.(2009).Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.ACTA OPHTHALMOLOGICA,87(7),736-740.
MLA Jiang, Yanrong,et al."Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy".ACTA OPHTHALMOLOGICA 87.7(2009):736-740.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jiang, Yanrong]的文章
[Liang, Xiaoying]的文章
[Li, Xiaoxin]的文章
百度学术
百度学术中相似的文章
[Jiang, Yanrong]的文章
[Liang, Xiaoying]的文章
[Li, Xiaoxin]的文章
必应学术
必应学术中相似的文章
[Jiang, Yanrong]的文章
[Liang, Xiaoying]的文章
[Li, Xiaoxin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。